antibody

Polyclonal Antibody to Complement Component 3 (C3)

MBS2005172

0.01 mg

110 USD

polyclonal

rabbit

nonconjugated

western blot, immunohistochemistry, immunocytochemistry, immunoprecipitation

Antibody

Polyclonal Antibody to Complement Component 3 (C3)

[Complement Component 3 (C3)]

[complement C3; Complement C3; complement C3; complement C3; Complement C3 beta chainC3-beta-c; C3bc]

[C3]

[C3; C3; C3bc; ENCF-2; ENCF-1; ASP]

Polyclonal

Rabbit

Antigen-specific affinity chromatography followed by Protein A affinity chromatography

Supplied as solution form in PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.

0.63mg/ml

Storage:. Avoid repeated freeze/thaw cycles. Store at 4ºC for frequent use. Aliquot and store at -20ºC for 12 months. Stability Test:. The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Western Blot (WB); Immunohistochemistry (IHC); Immunocytochemistry (ICC); Immunopreciptitation (IP).

Western blotting: 0.5-2ug/mL;1:300-1200. Immunohistochemistry: 5-20ug/mL;1:30-120. Immunocytochemistry: 5-20ug/mL;1:30-120. Optimal working dilutions must be determined by end user.

Western Blot (WB)

Immunohistochemistry (IHC)

Organism Species: Rattus norvegicus (Rat). Source: Polyclonal antibody preparation. Traits: Liquid

Immunogen: Recombinant Complement Component 3 (Asp966~Trp1313 (Accession # P01026)) expressed in E.coli ( MBS2012108 )

158138561

NP_058690.2

NM_016994.2

P01026

Activation Of C3 And C5 Pathway (1377188); Adaptive Immune System Pathway (1377120); Alternative Complement Activation Pathway (1377187); Chagas Disease (American Trypanosomiasis) Pathway (147806); Chagas Disease (American Trypanosomiasis) Pathway (147795); Class A/1 (Rhodopsin-like Receptors) Pathway (1376996); Complement Activation, Classical Pathway (198509); Complement And Coagulation Cascades Pathway (198461); Complement And Coagulation Cascades Pathway (83465); Complement And Coagulation Cascades Pathway (484)

putative complement component C3; likely involved in innate immune response [RGD, Feb 2006]

C3: C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates. Defects in C3 are the cause of complement component 3 deficiency (C3D). A rare defect of the complement classical pathway. Patients develop recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Some patients may also develop autoimmune disorders, such as arthralgia and vasculitic rashes, lupus-like syndrome and membranoproliferative glomerulonephritis. Genetic variation in C3 is associated with susceptibility to age-related macular degeneration type 9 (ARMD9). ARMD is a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin- containing structure known as Bruch membrane. Defects in C3 are a cause of susceptibility to hemolytic uremic syndrome atypical type 5 (AHUS5). An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype. Increased levels of C3 and its cleavage product ASP, are associated with obesity, diabetes and coronary heart disease. Short-term endurance training reduces baseline ASP levels and subsequently fat storage. Protein type: Inhibitor; Secreted; Secreted, signal peptide. Chromosomal Location of Human Ortholog: 9q12. Cellular Component: extracellular space; protein complex. Molecular Function: C5L2 anaphylatoxin chemotactic receptor binding; cofactor binding; endopeptidase inhibitor activity; lipid binding; protein binding. Biological Process: blood coagulation; chemotaxis; complement activation; complement activation, alternative pathway; complement activation, classical pathway; fatty acid metabolic process; inflammatory response; phagocytosis, engulfment; positive regulation of activation of membrane attack complex; positive regulation of angiogenesis; positive regulation of developmental growth; positive regulation of G-protein coupled receptor protein signaling pathway; positive regulation of phagocytosis; positive regulation of protein phosphorylation; positive regulation of type IIa hypersensitivity; response to estradiol; response to estrogen; response to glucocorticoid stimulus; response to magnesium ion; response to progesterone; tolerance induction

0.01 mg

110 USD

0.02 mg

125

0.05 mg

175

0.1 mg

225

0.2 mg

330

1 mg

785